GleamWall
中文EN

IMDX Insight Molecular Diagnostics Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1642380 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY520.9%
TTM net income YoY-40.9%
TTM EPS YoY27.5%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR—

Margins

Gross margin54.5%
Operating margin-1,392.9%
Net margin-1,380.7%
FCF margin-540.3%
EBITDA margin-1,343.0%

Returns

ROE-23,603.1%
ROA-106.5%
ROIC (approx.)—
Asset turnover0.08x

Leverage & solvency

Liabilities / assets120.9%
Debt / equity—
Current ratio2.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-68.2%
Payout ratio—
Capex / revenue43.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$559,000$239,000$32,000$1.14M$260,000$518,000$2.14M$1.49M
Cost of revenue$139,000$82,000$17,000$643,000$121,000$180,000$813,000$869,000
Gross profit$420,000$157,000$15,000$496,000$139,000$338,000$1.32M$595,000
R&D expense$3.79M$4.49M$4.95M$5.83M$3.88M$3.27M$2.92M$2.26M
SG&A expense$2.79M$2.87M$2.99M$2.33M$2.54M$2.65M$3.12M$2.56M
Operating income-$3.68M-$11.40M-$4.41M-$23.43M-$11.05M-$9.84M-$6.80M-$33.63M
Pretax income———————-$33.51M
Income tax$0$0$0$0$0$0$0$0
Net income-$3.58M-$11.26M-$4.29M-$22.95M-$10.85M-$9.74M-$6.67M-$33.51M
EBITDA-$3.03M-$10.74M-$3.78M-$22.87M-$10.46M-$9.28M-$6.31M-$33.06M
EPS (basic)-0.10-0.31-0.12—-0.34-0.30-0.26—
EPS (diluted)-0.10-0.31-0.12—-0.34-0.30-0.26—
Weighted avg. shares (diluted)36.86M36.75M34.52M—32.03M32.02M25.69M—
Banking
Net interest income-$17,000-$20,000-$23,000-$26,000-$29,000-$25,000-$29,000-$30,000
Balance sheet
Cash & equivalents$11.02M$17.76M$28.20M$11.58M$18.69M$24.29M$31.03M$8.64M
Receivables$520,000$192,000$157,000$1.13M$258,000$512,000$3.54M$1.61M
Inventory$372,000$207,000$382,000$446,000$471,000$693,000$459,000$410,000
Current assets$13.88M$20.54M$30.52M$15.31M$21.39M$26.84M$36.26M$11.76M
PP&E, net$5.55M$6.00M$8.91M$6.43M$5.80M$6.41M$6.79M$6.32M
Intangibles———$0$14.60M$14.60M$14.60M$14.61M
Total assets$21.74M$29.44M$40.43M$25.76M$43.94M$50.52M$60.36M$35.08M
Current liabilities$9.51M$10.29M$12.01M$12.07M$7.66M$6.65M$9.68M$7.28M
Total liabilities$45.92M$50.74M$51.12M$57.22M$53.13M$49.42M$50.14M$47.35M
Shareholders' equity-$24.18M-$21.30M-$10.69M-$31.46M-$9.20M$1.10M$10.22M-$12.27M
Shares outstanding32.76M32.62M32.29M28.68M28.63M28.62M28.60M17.45M
Cash flow statement
Operating cash flow-$6.43M-$9.27M-$7.64M-$5.54M-$4.50M-$6.17M-$5.84M-$5.35M
Capital expenditure$841,000$779,000$613,000$1.48M$1.05M$349,000$307,000$214,000
Free cash flow-$7.27M-$10.05M-$8.25M-$7.02M-$5.55M-$6.52M-$6.15M-$5.57M
Investing cash flow-$841,000-$779,000-$613,000-$1.48M-$1.05M-$349,000-$307,000-$210,000
Financing cash flow$370,000-$564,000$24.70M-$252,000-$120,000-$114,000$28.56M$10.84M
Depreciation & amortization$642,000$665,000$631,000$563,000$584,000$559,000$491,000$563,000
Stock-based compensation$820,000$661,000$615,000$721,000$521,000$504,000$473,000$499,000

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.